Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Truist Financial Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by investment analysts at Truist Financial from $769.00 to $772.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 5.24% from the company’s previous close.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $788.00.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ REGN opened at $733.58 on Friday. The firm has a fifty day simple moving average of $640.66 and a two-hundred day simple moving average of $711.35. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $77.55 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals will post 2.06 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. WPG Advisers LLC raised its position in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q2 results: Regeneron reported non-GAAP earnings of $14.29 per share, well above the approximately $10.16 consensus estimate, while revenue rose 16.7% year over year to $4.29 billion, surpassing expectations. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Core products delivered powerful growth: Dupixent sales, recorded by partner Sanofi, increased 38% to a record $6.0 billion, while U.S. EYLEA HD sales jumped 52% to a record $596 million. Libtayo sales also rose 30% to $489 million, helping offset declines in the original EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Additional shareholder return and pipeline support: The company declared a quarterly dividend of $0.94 per share. Investors are also watching potential long-term growth from investigational food-allergy therapies and a collaboration with Telix Pharmaceuticals to develop radiopharmaceutical oncology treatments.
• Neutral Sentiment: Valuation remains debated: Despite a roughly 36% gain over the past year and a trailing price-to-earnings ratio near 18, analysts characterize REGN as neither an obvious bargain nor clearly overvalued, leaving future pipeline execution and earnings growth central to the outlook. Regeneron Stock Looks Cheap On Earnings Yet Mixed Elsewhere
• Negative Sentiment: Clinical and legal overhang: Regeneron’s Phase 3 Fianlimab-Libtayo trial in advanced melanoma failed, prompting allegations that investors were misled about the study’s risks and protocol changes. Multiple law firms have announced or promoted securities class actions, citing the prior market-value loss. The litigation could increase reputational, financial and investor-confidence risks, although the announcements themselves do not represent findings of wrongdoing. Hagens Berman Regeneron investor alert

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.